Table 3.
Cross-resistance between the aminoglycosides gentamicin and neomycin, adjusted by demographic variables (logistic regression model)
| Independent variables | Gentamicin resistant | ||||
|---|---|---|---|---|---|
| Coefficient B |
SE | Risk | P | ||
| OR | IC95% | ||||
| Factor | |||||
| Neomycin MIC | 1,18 | 0,89 | 1,19 | 0,87-2,93 | 0,258 |
| Covariables | |||||
| Male Sex | 0,77 | 0,82 | 2,15 | 0,43-10,81 | 0,352 |
| Female Sex | 0,31 | 0,12 | 0,87 | 0,11-2,11 | 0,352 |
| Age (years) | 0,16 | 0,17 | 0,12 | 0,84-1,66 | 0,334 |
| Topical antibiotics use | 19,5 | 14,62 | 0,99 | 0,21-3,03 | 0,999 |
| Previous skin Infection | -0,15 | 1,12 | 0,86 | 0,09-7,71 | 0,894 |
| Recurrent cutaneous infections | -0,40 | 1,29 | 0,67 | 0,053-8,427 | 0,757 |
| Systemic antibiotics use | 2,15 | 1,54 | 3,29 | 0,88-18,54 | 0,214 |
| Hospitalization | 0,88 | 1,37 | 2,41 | 0,16-35,31 | 0,520 |
| Disease duration (years) £ | -0,121 | 0,17 | 0,88 | 0,63-1,24 | 0,483 |
| EASI score (points) £ | -0,01 | 0,04 | 0,99 | 0,91-1,01 | 0,828 |
SE: standard error. OR: odds ratio. £: model parameters: Pseudo-R2=0.237; -2 log Likelihood=46.750; Hosmer and Lemeshow (p=0.896).